What changed: HIV-associated (AIDS-related) lymphomas
Every dated change on the records linked to HIV-associated (AIDS-related) lymphomas, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval1Guideline1Milestone7This record1
September 2026 · 1
2021 · 1
2020 · 1
2019 · 1
2010 · 2
- 2010GuidelineHIV-associated (AIDS-related) lymphomasGuideline NCCN Guidelines: B-Cell Lymphomas (AIDS-related B-cell lymphomas); AMC 034 (Blood 2010): HIV-associated DLBCL
R-CHOP or dose-adjusted EPOCH-R at full dose with concurrent antiretroviral therapy (avoiding boosted protease inhibitors or cobicistat where possible), G-CSF support and opportunistic-infection prophylaxis; CNS prophylaxis by risk. (NCCN Category 2A)
- 2010MilestoneRituximabAMC 034: rituximab with EPOCH is safe and effective
Sparano and colleagues (Blood 2010) establish concurrent R-EPOCH.